Literature DB >> 11807162

Regulation of cyp3a gene transcription by the pregnane x receptor.

Bryan Goodwin1, Matthew R Redinbo, Steven A Kliewer.   

Abstract

The pregnane X receptor (PXR) is a promiscuous nuclear receptor that has evolved to protect the body from toxic chemicals. PXR is activated by a structurally diverse collection of xenobiotics, including several widely used prescription drugs. Various lipophilic compounds produced by the body, such as bile acids and steroids, also activate PXR. PXR stimulates the transcription of cytochrome P450 3A monooxygenases and other genes involved in the detoxification and elimination of these potentially harmful chemicals. Assays that detect PXR activation have important implications for the design of future drugs in two respects. On the one hand, PXR activation assays can be used to determine whether candidate drugs are likely to induce CYP3A gene expression and interact with other medicines. On the other hand, PXR agonists may prove useful in the treatment of diseases in which toxic metabolites accumulate, such as cholestatic liver disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11807162     DOI: 10.1146/annurev.pharmtox.42.111901.111051

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  83 in total

1.  CYP3A5 phenotype-genotype correlations in a British population.

Authors:  Barry P King; Julian B S Leathart; Elaine Mutch; Faith M Williams; Ann K Daly
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

2.  α-Tocopherol injections in rats up-regulate hepatic ABC transporters, but not cytochrome P450 enzymes.

Authors:  Maret G Traber; Edwin M Labut; Scott W Leonard; Katie M Lebold
Journal:  Free Radic Biol Med       Date:  2011-09-03       Impact factor: 7.376

3.  The Chinese herbal medicine Sophora flavescens activates pregnane X receptor.

Authors:  Laiyou Wang; Feng Li; Jie Lu; Guodong Li; Dan Li; Xiao-bo Zhong; Grace L Guo; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2010-08-24       Impact factor: 3.922

4.  Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Bernard H Shapiro
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

Review 5.  Pregnane X receptor and natural products: beyond drug-drug interactions.

Authors:  Jeff L Staudinger; Xunshan Ding; Kristin Lichti
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

6.  The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha.

Authors:  Fu-Jun Liu; Xiulong Song; Dongfang Yang; Ruitang Deng; Bingfang Yan
Journal:  Biochem J       Date:  2008-01-01       Impact factor: 3.857

7.  PAS kinase is required for normal cellular energy balance.

Authors:  Huai-Xiang Hao; Caleb M Cardon; Wojtek Swiatek; Robert C Cooksey; Tammy L Smith; James Wilde; Sihem Boudina; E Dale Abel; Donald A McClain; Jared Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-18       Impact factor: 11.205

8.  Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.

Authors:  Li-Qun Yang; Shen-Jing Li; Yun-Fei Cao; Xiao-Bo Man; Wei-Feng Yu; Hong-Yang Wang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

9.  Cyclic AMP-dependent protein kinase signaling modulates pregnane x receptor activity in a species-specific manner.

Authors:  Kristin Lichti-Kaiser; Chenshu Xu; Jeff L Staudinger
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

10.  Tumor suppressor protein p53 negatively regulates human pregnane X receptor activity.

Authors:  Ayesha Elias; Jing Wu; Taosheng Chen
Journal:  Mol Pharmacol       Date:  2013-03-27       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.